Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 本公司专业从事化学药品原料药及制剂的研发、生产和销售，产品疗效范围涉及关节炎类、利尿类、安神补脑类、抗病毒及抗肿瘤类等，主要产品包括盐酸氨基葡萄糖原料药及制剂、托拉塞米注射液及胶囊、天麻素原料药、利巴韦林及硫唑嘌呤原料药等。其中，盐酸氨基葡萄糖原料药及制剂、托拉塞米制剂及天麻素原料药主攻国内市场，利巴韦林及硫唑嘌呤原料药主要出口。本公司系由浙江诚意药业有限公司整体变更设立。2013年2月22日，浙江诚意药业有限公司召开股东会通过决议整体变更设立股份有限公司，并以截至2012年12月31日经中汇会计师事务所出具的中汇会审[2013]0129号《审计报告》得出的净资产225,107,135.75元为基准，扣除利润分配金额13,227,900.00元，剩余净资产211,879,235.75元，按3.3158：1的折股比例折合股份总数6,390.00万股，超过折股部分的净资产计入资本公积。2013年3月24日，中汇会计师事务所出具了中汇会验[2013]0707号《验资报告》，确认全体发起人股东出资都已缴纳完毕。2013年5月7日，浙江诚意药业股份有限公司正式取得温州市工商行政管理局颁发的注册号为330322000001788的《企业法人营业执照》。
Main Business 化学药品原料药及制剂的研发、生产和销售
Legal Representative 赵春建
Top Executives
董事长：颜贻意
副董事长：任秉钧
董事：柯泽慧,邱克荣,赵春建,厉市生,任秉钧
独立董事：金涛,陈志刚,夏法沪
Top 5 Shareholder
Shareholder name Nature Holding Date
颜贻意流通A股23.58%30/09/2024
全国社保基金六零四组合流通A股4.66%30/09/2024
岑均达流通A股2.46%30/09/2024
柯泽慧流通A股2.25%30/09/2024
任秉钧流通A股1.76%30/09/2024
Company Secretary 柯泽慧
Solicitors 上海市锦天城律师事务所
Auditors 中汇会计师事务所（特殊普通合伙）
Tel No 021-33283295
Fax No 021-33283305
Website www.chengyipharma.com
Email office@chengyipharma.com
Company Address
Register: 浙江省温州市洞头区化工路118号
Office: 上海市闵行区申虹路988弄富力悦都20幢9号7层
Listing Date 15/03/2017
Shares Capital
Shares Capital: 327,304,320
Total A Share: 327,304,320
Listed A Share: 327,304,320
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.500
DPS(RMB)* ¥ 0.200
NBV Per Share(RMB)* ¥ 3.643
Market Capitalization(RMB) 2.668B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.